Login
$PVLA
$144.90 +$0.30 (0.21%) After hours

$PVLA 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027

28 Oct 2026 8-K: Other Events

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

04 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026

14 Jul 2026 8-K: Other Events

First-in-disease therapies for patients with rare diseases Corporate Presentation July 2026

30 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 29, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Cor...

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

WHEREAS, Palvella Therapeutics, Inc. (the “Company”) maintains the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by t...

20 May 2026 8-K: Other Events

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare ...

15 May 2026 8-K: Other Events

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology

13 May 2026 8-K: Other Events

On May 11, 2026, Palvella Therapeutics, Inc. (the “Company”) received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effectiv...

07 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026

13 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 13, 2026 (the “Appointment Date”), the Board of Directors (the “Board”) of Palvella Therapeutics, Inc. (the “Company”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corp...

07 Apr 2026 8-K: Other Events

First-in-disease therapies for patients with rare diseases Corporate Presentation April 2026

31 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026

26 Feb 2026 8-K: Entry into a Material Definitive Agreement

TD Securities (USA) LLC Cantor Fitzgerald & Co. Stifel, Nicolaus & Company, Incorporated

24 Feb 2026 8-K: Results of Operations and Financial Condition

On February 24, 2026, Palvella Therapeutics, Inc. (the “Company”) announced that, as of December 31, 2025, the Company had approximately $55.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed...

24 Feb 2026 8-K: Regulation FD Disclosure

First-in-disease therapies for patients with rare diseases Phase 3 SELVA Topline Data in Microcystic Lymphatic Malformations February 24, 2026

24 Feb 2026 8-K: Other Events

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

29 Jan 2026 8-K: Other Events

First-in-disease therapies for patients with rare diseases Corporate Presentation January 2026

12 Jan 2026 8-K: Other Events

First-in-disease therapies for patients with rare diseases Corporate Presentation January 2026

15 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease w...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support